MedPath

The Effectiveness of Using E-Cigarettes for Smoking Cessation and Decreasing Risk of Diseases Among Heavy Smokers

Not Applicable
Withdrawn
Conditions
Smoking Cessation
Interventions
Other: Health Counselling
Combination Product: Electronic cigarettes + Health Counselling
Registration Number
NCT05639790
Lead Sponsor
Shenzhen Smoore Technology Limited
Brief Summary

The goal of this clinical trial is to evaluate effectiveness of using e-cigarettes as harm reduction strategy for smoking cessation and decreasing risk of diseases in heavy smokers. The main questions it aims to answer are:

* Is there any effectiveness of using E-cigarette as a harm reduction strategy for smoking cessation?

* what are the impacts of using E-cigarette on respiratory function and risk of COPD?

* Assess the exposure to harmful and potential harmful constituents (HPHCs) of using E-cigarette

Participants will be randomized into a 6 months single-center, open label trial comparing study outcomes among 2 arms: health counselling, E-cigarette + health counselling. The EC arm will receive EC for 1 month. All 2 arms will receive health counselling from a licensed mental health counselor. After baseline, participants will report their use of combustible cigarette in both arms and EC use in the EC arm every day via online questionnaire in Wechat for behavioral monitoring.

If there is a comparison group: Researchers will compare health counselling group to see if E-cigarrette intervention is an effective way to stop smoking, and if there any change in respiratory function and change in exposure to harmful and potential harmful constituents (HPHCs).

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • 18 to 60 years old, gender is not limited
  • The nicotine dependence test (FNDT) result score is 6-10 points
  • Self-reported smoking at least 10 cigarettes a day, and smoking for at least 3 years
  • Self-reported no current willingness to quit smoking
  • Self-reported difficulty controlling the need to smoke, or smoking while sick in bed
  • Must not accepted smoking cessation treatment in the last 3 months according to the self-report
  • Must have never tried e-cigarette before
  • Must be able to fully understand the purpose, nature and content of the research, and voluntarily sign the informed consent form as a subject
  • Must agree and able to communicate well with the researcher, and able to complete the online questionnaire and examination in accordance with the research regulations.
Exclusion Criteria
  • Self-reported pregnant or breastfeeding
  • Severe disease (defined as an illness or condition that put the patient at risk, interfere the trial results, or affect the patient's ability to participate in the trial judged by the panel)
  • Past diagnosis of COPD, lung cancer, pneumoconiosis, bronchiectasis, interstitial lung disease, bronchial asthma, or other restrictive ventilatory disorder
  • Living with severe heart, brain, liver, kidney, blood system diseases or malignant tumors
  • Moderate-severe renal impairment, or creatinine clearance (CCr) ≤50ml/min
  • Phenylpyruvaturia
  • Allergic predisposition (be allergic to two or more substances), and is allergic to any of the components in e-cigarettes or e-liquid (e.g., benzoic acid, propylene glycol, glycerin, nicotine, etc.)
  • Already been enrolled into a smoking cessation treatment, including but not limited to nicotine replacement therapy (NRT), varenicline, bupropion
  • Living with mental illness, a history of chronic alcoholism, drug abuse, or any factor that affects compliance
  • Participating in other clinical trials
  • Life-threatening condition with a life expectancy less than 1 year
  • Researcher believes that it is not suitable to participate in this researcher.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CounsellingHealth CounsellingHealth counselling from a licensed mental health counselor
Eletronic cigaretteElectronic cigarettes + Health CounsellingAd libitum use of electronic cigarettes for 1 month and health counselling from a licensed mental health counselor
Eletronic cigaretteHealth CounsellingAd libitum use of electronic cigarettes for 1 month and health counselling from a licensed mental health counselor
Primary Outcome Measures
NameTimeMethod
7-day point prevalence abstinence1 month

The effectiveness of smoking cessation with intervention

Secondary Outcome Measures
NameTimeMethod
Score of COPD-PS questionnaire1 month

self-reported score of COPD-PS questionnaire

%ratio of FEV1/FVC1 month

the proportion of a person's vital capacity that are able to expire in the first second of forced expiration (FEV1) to the full, forced vital capacity (FVC).

Concentration of 2-Cyanoethylmercaturic acid (CEMA)1 month

Concentration of 2-Cyanoethylmercaturic acid (CEMA) in urine

Score of COPD-SQ questionnaire1 month

self-reported score of COPD-SQ questionnaire

Score of CAT questionnaire1 month

self-reported score of COPD Assessment Test

Concentration of 3-Hydroxypropyl- mercapturic acid (3-HPMA)1 month

Concentration of 3-Hydroxypropyl- mercapturic acid (3-HPMA) in urine

Score of mMRC scale1 month

self-reported score of modified Medical Research Council scale

Concentration of S-benzyl-mercapturic acid (S-BMA)1 month

Concentration of S-benzyl-mercapturic acid (S-BMA) in urine

Concentration of cotinine1 month

Concentration of cotinine in urine

Concentration of Trans-3-Hydroxy Cotinine (TNE-2)1 month

Concentration of Trans-3-Hydroxy Cotinine (TNE-2) in urine

Concentration of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)1 month

Concentration of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in urine

Concentration of S-phenylmercapturic Acid (S-PMA)1 month

Concentration of S-phenylmercapturic Acid (S-PMA) in urine

Concentration of 3-Hydroxy-1-methylpropyl-mercapturic acid (3-HMPMA)1 month

Concentration of 3-Hydroxy-1-methylpropyl-mercapturic acid (3-HMPMA) in urine

Concentration of N-nitrosonornicotine (NNN)1 month

Concentration of N-nitrosonornicotine (NNN) in urine

Concentration of formic acid1 month

Concentration of formic acid in urine

Concentration of total Nicotine equivalent1 month

Concentration of total Nicotine equivalent in urine

© Copyright 2025. All Rights Reserved by MedPath